Frans Opdam

Frans Opdam has advanced understanding of clinically significant drug-drug interactions with oral tyrosine kinase inhibitors, demonstrating that CYP3A4-mediated interactions and acid-reducing agent co-administration are the most common causes of subtherapeutic TKI levels in clinical practice. His research showed that proton pump inhibitors reduce absorption of multiple TKIs including erlotinib, pazopanib, and dasatinib by 40-80%, with direct impact on treatment outcomes. He established clinical pharmacy guidelines for managing drug interactions in oncology patients receiving oral targeted therapies. His work on polypharmacy in cancer patients has improved the safe and effective use of oral oncology drugs.